Stock · NSE
DRREDDY 1,244.30 ▼ 25.20 (-1.99%) Last 2 days · 15m candles 10/7/2026, 22:32:11
Open: 1,268.40 High: 1,271.20 Low: 1,238.40 Prev: 1,269.50
VERIFIED ET Stocks · 18h ★ ON YOUR LIST ☆
Dr. Reddy's Lab among 4 F&O stocks that saw a high increase in futures open interest AI summary · NEUTRAL
· Futures open interest increased by over 11% in nine NSE F&O stocks on July 9. · Dr. Reddy's, Lodha Developers, Mazagon Dock, and HDFC Life saw significant rises in futures open interest. · This rise in open interest indicates fresh participation from traders. VERIFIED ET Finance · 22h ★ ON YOUR LIST ☆
Dr Reddy’s pauses weight loss drug on quality fears AI summary · NEGATIVE
· Dr Reddy's Laboratories is pausing semaglutide injection supplies until at least October due to identified impurities. · The company has assured that existing market products are safe for patient use. · Torrent Pharmaceuticals and USV Ltd are recalling semaglutide batches sourced from Dr Reddy's. Google News, NIFTY/SENSEX · 1d ★ ON YOUR LIST ☆
Nifty reclaims 24,000; midcaps outshine as Dr. Reddy’s tanks 5%, pharma diverges - BusinessLine Summarize with AI → Google News, NIFTY/SENSEX · 11d ★ ON YOUR LIST ☆
Nifty Pharma Index Hits Fresh 52-Week High; Dr Reddy’s, Cipla, Ajanta Pharma Lead Rally on GLP-1 Opportunity - India Infoline Summarize with AI → Google News, NIFTY/SENSEX · 11d ★ ON YOUR LIST ☆
Sensex, Nifty trade flat; Dr Reddy’s tops gainers, Kotak Bank leads losses - BusinessLine Summarize with AI → VERIFIED ET Markets · 25d ★ ON YOUR LIST ☆
Stocks in news: Dr Reddy’s, Adani Green, KIMS, JSW Energy, Nestle India AI summary · POSITIVE
· Nifty defended the 23,000 support and reclaimed 23,500. · Dr Reddy’s, Adani Green, and JSW Energy are in focus due to corporate developments. · Markets saw a strong rebound on Friday driven by positive global cues and easing geopolitical tensions. Google News, SEBI · 43d ★ ON YOUR LIST ☆
Dr. Reddy’s (NYSE: RDY) reports full SEBI compliance for FY 2026 - Stock Titan Summarize with AI → VERIFIED ET Finance · 51d ★ ON YOUR LIST ☆
Dr Reddy’s launches oral semaglutide in India AI summary · NEUTRAL
· Dr Reddy’s Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India, named Obeda. · Obeda is available in three tablet strengths for daily use. · Dr Reddy's is the second Indian company to introduce oral semaglutide domestically. VERIFIED ET Finance · 55d ★ ON YOUR LIST ☆
Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada AI summary · NEUTRAL
· Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. · Canada is the first G7 nation to approve this medication. · The launch follows a recent introduction in India. VERIFIED ET Stocks · 57d ★ ON YOUR LIST ☆
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27 AI summary · POSITIVE
· Dr Reddy's Laboratories expects a gradual recovery this fiscal year, following a profit drop last year due to US business pressures. · Operations in India, Europe, and emerging markets are demonstrating healthy growth. · New product launches, including Semaglutide and Abatacept, are projected to fuel future expansion, with anticipated margin improvements from a better product mix and cost controls. VERIFIED Mint Markets · 58d ★ ON YOUR LIST ☆
Dr Reddy's Laboratories shares volatile after an 86% YoY decline in Q4 profit. Should you buy? AI summary · NEGATIVE
· Dr Reddy's Laboratories reported an 86% year-on-year decline in Q4 profit. · The company's shares experienced volatility on Wednesday, 13 May. · During the session, shares rose nearly 3% before plunging 4%.